Abvc Biopharma (ABVC) Non Operating Income (2015 - 2026)
Abvc Biopharma's (ABVC) quarterly Non Operating Income came in at -$117465.0 in Q1 2026, up 53.24% YoY from -$76656.4 in Q1 2025, and up 85.63% on a QoQ basis from -$817552.0 in Q4 2025.
Abvc Biopharma (ABVC) Non Operating Income (2015 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 12 years of Non Operating Income data on file, last reported at -$117465.0 in Q1 2026.
- Quarterly Non Operating Income rose 53.24% year-over-year to -$117465.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.1 million (down 29.26% YoY) and the FY2025 annual result came in at -$1.2 million, down 80.86% from the prior year.
- Non Operating Income rose to -$117465.0 in Q1 2026, from -$817552.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $8954.0 in Q1 2023 to a low of -$1.2 million in Q3 2023.
- A 5-year average of -$232204.2 and a median of -$104714.0 in 2024 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income plunged 13353.52% — and 2023, when it surged 195.15%.
- Tracing ABVC's Non Operating Income over 5 years: stood at -$9410.0 in 2022, then sank by 39.89% to -$13164.0 in 2023, then slumped by 598.59% to -$91963.0 in 2024, then tumbled by 789.0% to -$817552.0 in 2025, then soared by 85.63% to -$117465.0 in 2026.
- The last three Non Operating Income figures came in at -$117465.0 (Q1 2026), -$817552.0 (Q4 2025), and -$118586.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | -30,955.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30,955.00 |
| Mar 31, 2026 | -117,465.00 |
| Dec 31, 2025 | -817,552.00 |
| Sep 30, 2025 | -118,586.00 |
| Jun 30, 2025 | -14,223.00 |
| Mar 31, 2025 | -251,185.00 |
| Dec 31, 2024 | -91,963.00 |
| Sep 30, 2024 | -184,760.00 |
| Jun 30, 2024 | -298,199.00 |
| Mar 31, 2024 | -89,412.00 |
| Dec 31, 2023 | -13,164.00 |
| Sep 30, 2023 | -1.21 Mn |
| Jun 30, 2023 | -39,688.00 |
| Mar 31, 2023 | 8,954.00 |
| Mar 31, 2022 | -9,410.00 |
| Dec 31, 2021 | 557,105.00 |
| Sep 30, 2021 | 8,643.00 |
| Jun 30, 2021 | -77,005.00 |
| Mar 31, 2021 | 71.00 |
| Dec 31, 2020 | -204,920.00 |